tbuckley/cabot-search huggingface dataset:
Abstract 9369: Nanoparticle-mediated Delivery of TT-10 Promotes Cardiomyocyte Proliferation and Myocardial Repair
Authors: Wangping Chen, Danielle Pretorius, Yang Zhou, Jianyi Zhang
Journal: Circulation (2021)

The pharmaceutical product TT-10 increases cardiomyocyte proliferation and survival by upregulating nuclear levels of Yes-associated protein (Yap) and the expression of Yap-targeted genes. When evaluated in a mouse model of myocardial infarction (MI), intraperitoneal TT-10 administration was associated with improvements in infarct size and cardiac function 1 week after treatment, but functional parameters progressively declined at later time points [1]. Here, we tested our hypothesis that the potency of TT-10 for myocardial repair could be increased by loading it into poly-lactic-co-glycolic acid nanoparticles (NPs) before intramyocardial administration. Mice were treated with injections of DPBS (n=9), empty nanoparticles (Empty-NPs, n=8), TT-10 solution (TT-10-sol, n=8), or TT-10-loaded NPs (TT-10-NPs, n=9) immediately after MI was induced via permanent ligation of the coronary artery. Cardiac function was assessed via echocardiography, infarct size via histological Fast-Green staining, cardiac hypertrophy via measures of the heart-weight:bodyweight (HW:BW) ratio, cardiomyocyte proliferation via staining for Ki67 and phosphorylated histone 3 (PH3), and apoptosis via TUNEL. In vitro assessments confirmed that TT-10 was released from the TT-10-NPs for up to 4 weeks, and that the NPs were taken up by cultured cardiomyocytes. 1 and 4 weeks after MI induction and treatment, measures of left-ventricular (LV) ejection fraction (EF) and fractional shortening (FS) were significantly greater in TT-10-NP animals than in the TT-10-sol, Empty-NP, or DPBS groups; LV EF and FS also remained stable in the TT-10-NP group, while measurements in all other groups worsened (but not significantly), between the two time points. TT-10-NP treatment was also associated with significantly smaller (by ~20%, p&lt;0.05) infarcts and significantly lower HW:BW ratios at Week 4; with significantly greater proportions of Ki67 + , PH3 + , and nuclear-Yap + cardiomyocytes at Week 1; and with significant declines in TUNEL + cardiomyocytes 72 hours after MI and treatment. Thus, NP-mediated delivery of TT-10 results in the efficacy of both the magnitude and durability of the benefits associated with promotion of myocyte proliferation in a mouse MI model. [1]. PMID: 30456335
Reply to Laurence Klotz’s Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of “Manels” in Major Urology Meetings. Eur Urol 2021;80:442–9. Eur Urol 2021;80:e100
Authors: M Carmen Mir, Tamsin Greenwell, Fardod O'Kelly, Silvia Proietti, Ekaterina Laukhtina, Laura Mertens, Saskia Morgenstern, Idir Ouzaid
Journal: European Urology (2021)
Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis
Authors: Danny Luan, Christopher R. Flowers, Brian K. Link, Jonathan W. Friedberg, Jonathon B. Cohen, Brad S. Kahl, Izidore S. Lossos, Loretta Nastoupil, Matthew J. Maurer, James R. Cerhan, Peter Martin
Journal: Blood (2021)
An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis
Authors: Batuhan Yenilmez, Nicole Wetoska, Mark Kelly, Dimas Echeverria, Kyounghee Min, Lawrence Lifshitz, Julia F. Alterman, Matthew R. Hassler, Samuel Hildebrand, Chloe DiMarzio, Nicholas McHugh, Lorenc Vangjeli, Jacquelyn Sousa, Meixia Pan, Xianlin Han, Michael A. Brehm, Anastasia Khvorova, Michael P. Czech
Journal: Molecular Therapy (2021)

Nonalcoholic steatohepatitis (NASH) is a severe liver disorder characterized by triglyceride accumulation, severe inflammation, and fibrosis. With the recent increase in prevalence, NASH is now the leading cause of liver transplant, with no approved therapeutics available. Although the exact molecular mechanism of NASH progression is not well understood, a widely held hypothesis is that fat accumulation is the primary driver of the disease. Therefore, diacylglycerol O-acyltransferase 2 (DGAT2), a key enzyme in triglyceride synthesis, has been explored as a NASH target. RNAi-based therapeutics is revolutionizing the treatment of liver diseases, with recent chemical advances supporting long-term gene silencing with single subcutaneous administration. Here, we identified a hyper-functional, fully chemically stabilized GalNAc-conjugated small interfering RNA (siRNA) targeting DGAT2 (Dgat2-1473) that, upon injection, elicits up to 3 months of DGAT2 silencing (>80%-90%, p < 0.0001) in wild-type and NSG-PiZ "humanized" mice. Using an obesity-driven mouse model of NASH (ob/ob-GAN), Dgat2-1473 administration prevents and reverses triglyceride accumulation (>85%, p < 0.0001) without increased accumulation of diglycerides, resulting in significant improvement of the fatty liver phenotype. However, surprisingly, the reduction in liver fat did not translate into a similar impact on inflammation and fibrosis. Thus, while Dgat2-1473 is a practical, long-lasting silencing agent for potential therapeutic attenuation of liver steatosis, combinatorial targeting of a second pathway may be necessary for therapeutic efficacy against NASH.
Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production
Authors: John Mascarenhas, Heidi E. Kosiorek, Rupali Bhave, Jeanne M. Palmer, Andrew T. Kuykendall, Ruben A. Mesa, Raajit Rampal, Aaron T. Gerds, Abdulraheem Yacoub, Kristen M. Pettit, Moshe Talpaz, Rami S. Komrokji, Marina Kremyanskaya, Agapito Gonzalez, Frank Fabris, Lonette Sandy, Kathryn Johnson, Mikaela Doughtery, Erin McGovern, Juan Arango Ossa, Dylan Domenico, Noushin Farnoud, Anna Rita Migliaccio, Mohamed E Salama, Rona Singer Weinberg, Amy Kong, Vesna Najfeld, Carolyn Mead-Harvey, Amylou C. Dueck, Lilian Varricchio, Ronald Hoffman
Journal: Blood (2021)
Posttransplant Cyclophosphamide-Based Haploidentical Vs Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia
Authors: Kyung Taek Hong, Hyun Jin Park, Bo Kyung Kim, Hong Yul An, Jung Yoon Choi, Hyoung Jin Kang
Journal: Blood (2021)
Abstract 9385: Sacubitril-Valsartan (lcz-696) Improves Ejection Fraction and Longitudinal Strain in Mice Exposed to Doxorubicin Through Nlrp3 Inflammasome, Myd88 Myddosome and Chemokines
Authors: Nicola Maurea, Andrea Paccone, Simona Buccolo, Martina Iovine, Domenica Rea, Antonio Barbieri, Francesca Cerrone, Vincenzo Quagliariello
Journal: Circulation (2021)

Introduction: Doxorubicin-mediated adverse cardiovascular events are among the leading causes of morbidity and mortality in breast cancer patients. Sacubitril-valsartan (LCZ 696) is a combination drug, made up of neprilysin inhibitor sacubitril and angiotensin II receptor blocker valsartan, used for the treatment of heart failure in patients with a reduced ejection fraction. Hypothesis: we hypothesized that LCZ 696, administered during doxorubicin, could improve cardiac function and cardiac inflammation in preclinical models Methods: Human fetal cardiomyocytes (HFC cell line) were exposed to subclinical concentration of doxorubicin (200 nM) alone or in combination with LCZ-696 (100 mM) for 72 h. After the incubation period, we performed the following tests: cell viability, apoptosis and necrosis; expression of MDA and 4HNA and concentration of intracellular Ca 2+ . Moreover, pro-inflammatory studied were also performed (activation of NLRP3; expression of TLR4/MyD88; mTORC1 Fox01/3a; NF-κB). C57Bl/6 mice were untreated (Sham, n=6) or treated for 10 days with doxorubicin i.p at 2.17 mg/kg (DOXO, n=6), LCZ-696 at 60 mg/kg (LCZ, n=6) or doxorubicin combined to LCZ-696 (DOXO-LCZ, n=6). Ejection fraction, radial and longitudinal strain were analyzed through transthoracic echocardiography (Vevo 2100). Cardiac tissue expression of NLRP3, Myd88, NF-kB and chemokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL17-α, IL-18, IFN-γ, TNF-α, G-CSF, and GM-CSF) were quantified. Results: LCZ-696 exerts cardioprotective effects, enhancing cell viability of 48-55% compared to only doxorubicin-treated cells (p&lt;0,001 for all); LCZ 696 decreased NLRP3, MyD88 and NF-kB expression in cardiac cells. In preclinical study, LCZ 696 improved significantly the EF and prevented the reduction of radial and longitudinal strain after 10 days of treatment with doxorubicin. A reduced expression of NLRP3, MyD88 and NF-kB in cardiac tissues was seen in DOXO-LCZ group compared to DOXO mice (p&lt;0.001). Cardiac expression of IL-1β, IL-6, TNF-α, G-CSF and GM-CSF were significantly reduced after treatment with LCZ-696. Conclusions: LCZ-696 reduced inflammation and cytokine expression involved in doxorubicin-mediated cardiotoxicity, improving cardiac functions.
First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006)
Authors: Clare J Rowntree, Amy A Kirkwood, Laura Clifton-Hadley, Nadine Farah, Marc R. Mansour, Jiaull Hussain, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Pip Patrick, Bela Wrench, Adele K. Fielding
Journal: Blood (2021)
Establishing a Novel Pipeline That Combines <i> in-Silico</i> Prediction with <i>in-Vitro</i> and <i> Ex-Vivo V</i>alidation to Discover Secondary Drug Combinations Against Relapsed and/or Refractory Multiple Myeloma
Authors: Sayak Chakravarti, Suman Mazumder, Harish Kumar, Neeraj Sharma, Ujjal Kumar Mukherjee, Shaji Kumar, Linda B Baughn, Brian G. Van Ness, Amit Kumar Mitra
Journal: Blood (2021)
Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study
Authors: Biree Andemariam, Timothy Mant, Perla Eleftheriou, Sanne Lugthart, Lanetta Bronté-Hall, Filipa Barroso, Gershwin Blyden, James Mason, Constance M Barysauskas, Joseph Yen, Karen Tang, Rahul Ballal, Kenneth Attie
Journal: Blood (2021)
Genomic Landscape of <i>RUNX1</i>-Familial Platelet Disorder with Myeloid Malignancies Reveals Rising Clonal Hematopoiesis
Authors: Kai Yu, Matthew Merguerian, Natalie Deuitch, Erica Bresciani, Joie Davis, Kathleen Craft, Lea C. Cunningham, Paul P. Liu
Journal: Blood (2021)
BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction
Authors: Theodora Alese, Benjamin G Barwick, Vikas A. Gupta, Nisha Joseph, Craig C. Hofmeister, Mala Shanmugam, Jonathan L. Kaufman, Madhav V Dhodapkar, Sagar Lonial, Ajay K. Nooka, Lawrence H. Boise
Journal: Blood (2021)
Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?
Authors: Rakesh Popat, Ashraf Z. Badros, Shaji Kumar, Paula Rodríguez-Otero, Adam D. Cohen, Salomon Manier, Peter M. Voorhees, Francesca Gay, Robert M. Rifkin, Thomas Martin, Ajai Chari, Katja Weisel, Asim V. Farooq, Bennie H. Jeng, Wee Joo Chng, Hans C. Lee, Jesus Berdeja, Vinay Jadhav, Alessandra Tosolini, Laurie Eliason, Antonio Palumbo, Meletios A. Dimopoulos, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, Evangelos Terpos
Journal: Blood (2021)
Abstract 12672: A New Genetic Model Organism for Primate-Specific Cardiac Function and Disease
Authors: Stephen Chang, Mark Krasnow
Journal: Circulation (2021)

Introduction: Due to differences in cardiac structure and function, it has become increasingly clear that many aspects of cardiovascular disease are not well modeled in mice. This has spurred a search for new model organisms with the practical advantages of mice but that more closely mimic human biology. This study examines mouse lemur (Microcebus species) - the world’s smallest, most prolific, and among the most abundant non-human primates - and the cheapest and easiest to maintain, as such a model. Methods: This study characterizes the normal cardiac anatomy and histology, and baseline values for heart rate, cholesterol, and cardiac waveform by ECG (a point-of-care blood assay and a portable 3-lead monitoring device were used to screen ~400 animals). It also describes the development of a whole genome and single cell RNA-sequencing and analysis pipeline for Microcebus murinus. Results: Transcriptomic analysis identified 6000 cardiac cells, including all major and many minor cardiac cell types, including several exceedingly rare cell types. The lipid profiles of these animals more closely resembled that of humans, with an average LDL level of 81 mg/dL, with several obese animals having values &gt;200. 20 naturally-occurring ECG variants were identified, all resembling known human ECG variants including 8 major cardiac arrhythmias. The screen uncovered the first cases of heart disease in lemurs. One is atrial fibrillation; Another is sick sinus syndrome (SSS), whose human familial form arises from mutations in ion channel genes, HCN4 or SCN5A. Both arrythmias show familial clustering, with the SSS pedigree exhibiting an autosomal dominant inheritance pattern. SNP/variant analysis revealed 30 million variants in the SSS animals, and ongoing work has narrowed these to just a handful of high impact, functional variants in SCN5A, suggesting that the underlying mouse lemur SSS disease gene and causative mutation are the same as in humans. Conclusions: The results establish the mouse lemur as the first systematic, high-throughput primate genetic model for cardiovascular physiology and disease, and reveal human-like cardiac cell types and diseases. The approach uncovered naturally-occurring cardiac diseases that have not been found in mice.
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the <scp>DIAMOND</scp> trial
Authors: Javed Butler, Stefan D. Anker, Tariq Jamal Siddiqi, Andrew J.S. Coats, Fabio Dorigotti, Gerasimos Filippatos, Tim Friede, Udo‐Michael Göhring, Mikhail N. Kosiborod, Lars H. Lund, Marco Metra, Carol Moreno Quinn, Ileana L. Piña, Fausto J. Pinto, Patrick Rossignol, Peter Szecsödy, Peter Van Der Meer, Matthew Weir, Bertram Pitt
Journal: European Journal of Heart Failure (2021)

In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+ ) binder, may improve serum K+ levels and adherence to RAASi.The DIAMOND trial will enroll ∼820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocorticoid receptor antagonist (MRA) titrated to 50 mg/day and other RAASi therapy to ≥50% target dose, and patiromer. Patiromer will be titrated up to a maximum three packs/day (8.4 g/pack) to achieve optimal doses of RAASi without hyperkalaemia. The run-in phase will last up to 12 weeks, following which patients will undergo double-blind randomization in a 1:1 ratio to receive either continued patiromer or placebo (patiromer withdrawal). The primary endpoint is the mean difference in serum K+ from randomization between patiromer and placebo arms. Secondary endpoints will include hyperkalaemia events with K+ value >5.5 mEq/L, durable enablement of MRA at target dose, investigator-reported adverse events of hyperkalaemia, hyperkalaemia-related clinical endpoints and an overall RAASi use score (using a 0-8-point scale) comprising all-cause death, occurrence of cardiovascular hospitalization or usage of comprehensive heart failure medication.The DIAMOND trial is designed to determine if patiromer can favourably impact K+ control in patients with HFrEF with hyperkalaemia or a history of hyperkalaemia leading to RAASi therapy compromise, and in turn improve RAASi use.
Central Memory T-Cell Differentiation Correlates with Depth of Response in Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (Elo-KRd)
Authors: David M Foureau, Manisha Bhutani, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Reed Friend, Barry Paul, Myra M Robinson, James T Symanowski, Lawrence J Druhan, Mauricio Pineda-Roman, Peter M. Voorhees, Saad Z. Usmani
Journal: Blood (2021)
Over-Expression of CRLF2 By Flow Cytometry (FC) Impacts on Overall Survival (OS) in Mexican Patients with Acute Lymphoblastic Leukemia (ALL)
Authors: Emmanuel Almanza Huante, Juan Rangel-Patiño, Rosana Daniela Córdova-Serrano, Karla Adriana Espinosa, Roberta Demichelis
Journal: Blood (2021)
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
Authors: Andrew M Leader, John A Grout, Barbara B Maier, Barzin Y Nabet, Matthew D Park, Alexandra Tabachnikova, Christie Chang, Laura Walker, Alona Lansky, Jessica Le Berichel, Leanna Troncoso, Nausicaa Malissen, Melanie Davila, Jerome C Martin, Giuliana Magri, Kevin Tuballes, Zhen Zhao, Francesca Petralia, Robert Samstein, Natalie Roy D'Amore, Gavin Thurston, Alice O Kamphorst, Andrea Wolf, Raja Flores, Pei Wang, Sören Müller, Ira Mellman, Mary Beth Beasley, Hélène Salmon, Adeeb H Rahman, Thomas U Marron, Ephraim Kenigsberg, Miriam Merad
Journal: Cancer Cell (2021)
Early Bone Marrow Assessment after 7+3 Induction Chemotherapy Is Predictable of Outcome in AML with Adverse Cytogenetics
Authors: Daehun Kwag, Byung-Sik Cho, Gi-June Min, Sung-Soo Park, Silvia Park, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Hee-Je Kim
Journal: Blood (2021)
Biology and Clinical Implications of Complex Landscape of Cooperating Events in <i>FLT3</i>-ITD Acute Myeloid Leukemia
Authors: Katherine Tarlock, Leila Robinson, Todd A. Alonzo, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Amanda R. Leonti, Jenny L. Smith, Tiffany A. Hylkema, Quy Le, Xiaotu Ma, E. Anders Kolb, Richard Aplenc, Jessica A. Pollard, Soheil Meshinchi
Journal: Blood (2021)
Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment
Authors: Tammuella Chrisentery-Singleton, W Allan Alexander, Ahmad Al-Sabbagh, Daniel Bonzo, Michael U. Callaghan, Miguel A. Escobar, Adam Giermasz, Nikki Hirsh, Janna Journeycake, Sonia Nasr, Doris V. Quon, Michael Recht
Journal: Blood (2021)
Pre-Infusion Neurofilament Light Chain (NfL) Levels Predict the Development of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) - a Multicenter Retrospective Study
Authors: Omar H Butt, Alice Y. Zhou, Paolo F. Caimi, Paul-Robert Derenoncour, Kenneth Lee, Gregory F Wu, Marcos J.G. de Lima, John F. DiPersio, Jian L. Campian, Armin Ghobadi, Beau M Ances
Journal: Blood (2021)
Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy
Authors: Ruixin Li, Guangsheng He, Xi Chen, Zhengyuan Liu, Yan Yang, Shengyun Lin, Jinsong Jia, Yuanyuan Jin, Qiqiang Long, Xiaoqing Liu, Lang Cheng, Jiongtao Zhou, Jianyong Li
Journal: Blood (2021)
Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy
Authors: Nicolas Gazeau, Pere Barba, Gloria Iacoboni, Mi Kwon, Rebeca Bailen, Juan Luis Reguera, Lucía López Corral, Rafael Hernani, Valentín Ortiz-Maldonado, Antonio Perez-Martinez, Richard T. Maziarz, Staci Williamson, Eneida R. Nemecek, Mazyar Shadman, Andrew Coman, Damian J. Green, Victor A. Chow, Alexandre V. Hirayama, David G. Maloney, Cameron J. Turtle, Jordan Gauthier
Journal: Blood (2021)
Improvement in Outcomes of Autologous Stem Cell Transplant in Patients with Lymphoma Older Than 70 Years: The Significance of Age in 2020s?
Authors: Kitsada Wudhikarn, Bradley K. Johnson, Jose C. Villasboas, Jonas Paludo, David J. Inwards, Luis F. Porrata, Ivana N. Micallef, Stephen M. Ansell, Patrick B. Johnston
Journal: Blood (2021)
Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study
Authors: Patrick Van Dreden, Joseph Gligorov, Evangelos Terpos, Mathieu Jamelot, Michele Sabbah, Despina Fotiou, Aboubakr Ka, Joanna Charitaki, Ismail Elalamy, Tina Bagratuni, Jawed Fareed, Aurélie Rousseau, Meletios A. Dimopoulos, Grigoris Gerotziafas
Journal: Blood (2021)
Abstract 9327: Risk Factors for Adverse Outcomes in Term Infants With Congenital Heart Disease and Necrotizing Enterocolitis
Authors: Anna M Bakas, Katie Moynihan, Robert Przybylski, Nancy Braudis, Bethany Farr, Biren P Modi, Kimberly I Mills, Meena Nathan, Philip T Levy
Journal: Circulation (2021)

Introduction: Infants with congenital heart disease (CHD) are at increased risk of developing necrotizing enterocolitis (NEC), with mortality rates up to 57%. The aim of this study was to investigate pre-NEC factors associated with adverse outcomes in term infants with CHD-NEC. Methods: We performed a 20-year (2000-2020) single-institution retrospective cohort study in term infants (&gt;37 weeks) &lt;6 months of age admitted to the Boston Children’s Hospital Cardiac Intensive Care Unit with CHD-NEC (Bell’s stage &gt; 2). The primary outcome was a composite of in-hospital mortality and post-NEC morbidity (extracorporeal life support or surgical NEC). Predictors included baseline admission patient characteristics, cardiac diagnosis and intervention, feeding regimen, and severity of illness, as measured with the pediatric sequential organ failure assessment (pSOFA) score. Results: We identified 82 patients with CHD-NEC from 3933 admissions (prevalence, 2.1%), including 54 (66%) duct dependent and 55 (67%) with NEC post cardiac surgery. Twenty-seven (33%) met the primary outcome, (in-hospital mortality in 14 (17%) with 9 (64%) attributed to NEC). In univariate analysis, pre-NEC factors significantly associated with the primary outcome included female sex, fetal growth restriction, systolic dysfunction, older age and weight at NEC ( Table ). Feeding regimen (formula, caloric density), genetic conditions, APGARs, race, cardiac lesion, outflow tract z-score or STAT category had no impact on outcome. In multivariable analysis, peri-NEC pSOFA, lower weight and older age at NEC diagnosis remained significantly associated with the primary outcome (Table) . Conclusions: Radiologically-proven NEC occurred in 2% of term infants with CHD, with death and adverse post-NEC outcomes in more than one-third. Lower weight and older age at diagnosis were associated with adverse outcomes informing risk-triage and prognostic counseling for families.